{"id":"NCT00541385","sponsor":"Medicines for Malaria Venture","briefTitle":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","officialTitle":"Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-09","completion":"2008-11","firstPosted":"2007-10-10","resultsPosted":"2021-11-22","lastUpdate":"2021-11-22"},"enrollment":535,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malaria"],"interventions":[{"type":"DRUG","name":"pyronaridine artesunate","otherNames":["Pyramax"]},{"type":"DRUG","name":"arthemeter lumefantrine","otherNames":["Coartem"]}],"arms":[{"label":"PA group","type":"EXPERIMENTAL"},{"label":"AL group","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%.\n\nSecondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \\[AL\\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.","primaryOutcome":{"measure":"Percentage of Participants With PCR-Corrected ACPR on Day 28","timeFrame":"Day 28","effectByArm":[{"arm":"PA Group","deltaMin":97.6,"sd":null},{"arm":"AL Group","deltaMin":98.8,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.3728"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Burkina Faso","Côte d’Ivoire","Democratic Republic of the Congo","Gabon","Kenya","Mali","Mozambique","Philippines"]},"refs":{"pmids":["23113947","38418982","26666916","23433102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":355},"commonTop":["Cough","Upper respiratory tract infection","Platelet count increased","Blood glucose decreased","Anaemia"]}}